Brazil Hits 873,000 Medical Cannabis Patients as Latin America Booms

While most of the global cannabis conversation in 2026 has centered on U.S. rescheduling and European medical expansion, Latin America's largest economy has quietly built one of the largest medical cannabis programs in the world. Brazil now reports more than 873,000 registered medical cannabis patients — putting the country in the same league as Germany, which has between 700,000 and 900,000 medical patients. With annual cannabis revenue approaching $200 million and a regulatory framework that just opened the door to domestic cultivation, Brazil is rapidly becoming the most consequential cannabis story south of the equator.

The patient count, the regulatory pivot and the 2026 Cannabis Fair at São Paulo's Transamérica Expo Center (May 21–23, 2026) together point to a market in transition: from import-dependent, judge-by-judge access to a structured, increasingly local industry that international operators are watching closely.

A Patient Base That Rivals Europe's Largest Markets

Eight hundred and seventy-three thousand is not a small number. To put it in context, that figure puts Brazil ahead of every European medical cannabis program except Germany, and ahead of every U.S. state medical-only program by patient count. It also represents a remarkable arc for a country whose first ANVISA-approved cannabis product hit shelves only in 2020.

Two structural factors drive that growth. First, Brazil's medical cannabis program operates through a hybrid model: ANVISA — the national health regulator — authorizes specific imported cannabis-based products for sale in pharmacies, while a parallel system of judicial authorizations (habeas corpus rulings) allows individual patients to import or cultivate for personal use. Second, the country's universal health system (SUS) has incrementally added cannabis-based medicines to its formulary for specific conditions, dramatically lowering out-of-pocket cost for qualifying patients.

Together those tracks create a steady pipeline of new patient registrations, and the regulator has continued to expand the list of qualifying products and pathways. The result is a market that grew from a handful of pilot prescriptions to nearly nine hundred thousand active patients in roughly five years.

The 2026 ANVISA Pivot: Domestic Cultivation Is Finally On the Table

For most of its history, Brazil's medical cannabis market has been a finished-product import market. Prescriptions are filled with European, Israeli, Australian, Canadian or U.S. cannabis-based oils and capsules. That has kept prices high and pushed many patients toward judicial workarounds.

That structure is now changing. In early 2026, ANVISA expanded its rules to allow selected patient associations to cultivate cannabis for medical purposes — a major shift in a country where domestic cultivation has historically required individual court orders. The expanded framework gives qualifying associations a regulated pathway to grow, process and distribute cannabis-based medicines to their members under defined oversight. It also opens the conceptual door to broader domestic cultivation rules in coming years.

The economics are obvious. Locally cultivated cannabis can be sold to patients for a fraction of the cost of imported finished oils, and a domestic supply chain reduces foreign-exchange exposure for a market still measuring revenue in reais. For international operators, the pivot signals that the import-only era is closing, and that long-term Brazilian opportunity will increasingly require local cultivation, partnership or licensing strategies rather than pure export plays.

A $200 Million Market — and the Headroom Above It

Brazil's medical cannabis market is now approaching $200 million in annual revenue. That sounds small next to multibillion-dollar U.S. state markets, but it is a misleading comparison. Brazil's pricing is constrained by import costs, judicial complexity and conservative ANVISA product limits. Volume — measured in patients and prescriptions — is enormous and still expanding rapidly.

International market analysts have for several years pegged Brazil as a multi-billion-dollar mid-decade opportunity, contingent on the regulator's willingness to open domestic cultivation, broaden product categories and integrate cannabis-based medicines more deeply into SUS coverage. The 2026 cultivation expansion is the most consequential of those triggers to fire so far.

If domestic cultivation scales meaningfully and ANVISA continues to add product categories, Brazil could plausibly become the largest medical cannabis market in the Americas outside the United States by the end of the decade — surpassing Mexico (whose framework has stalled in implementation), Colombia (an export-focused producer with a small domestic market) and Argentina (a smaller but rapidly maturing program).

Why São Paulo's Cannabis Fair Matters in 2026

The fifth edition of Cannabis Fair — running May 21 to 23, 2026 at the Transamérica Expo Center in São Paulo — is positioning itself as Latin America's primary cannabis business gathering. Exhibitors are coming in from Brazil, the United States, Colombia and Uruguay, and the agenda is heavily oriented toward investment, regulatory navigation and cross-border supply.

For U.S. operators in particular, the fair is becoming a key calendar event for two reasons. First, it offers direct exposure to the largest patient base in the region. Second, with U.S. federal rescheduling now complete and 280E pressure relieved, multi-state operators have new capital flexibility to consider international plays — and Brazil is the obvious foothold market for Latin America. Cresco Labs, Curaleaf, Verano Holdings and Trulieve are all on the list of operators with rumored interest in international diversification post-rescheduling.

The event also highlights the maturing investor ecosystem in Latin American cannabis: dedicated funds, family offices and pharmaceutical partners are increasingly active at industry conferences, looking for cultivation, extraction and distribution opportunities the U.S. market is too saturated to offer at attractive valuations.

What to Watch Next

Three signals will tell whether Brazil's market continues to compound. First, how rapidly ANVISA expands the cultivation framework beyond patient associations into commercial cultivation tiers. Second, whether SUS coverage expands to cover additional cannabis-based medicines for additional conditions, which would meaningfully reduce out-of-pocket cost for the existing patient base. Third, whether Congress — historically more conservative on drug policy — moves any of the standing cannabis bills currently in committee. None are guaranteed, but each would mark another inflection point in a market that has consistently surprised observers with its pace of growth.

For now, the headline number — 873,000 patients — does most of the work. Brazil has, almost without fanfare, built one of the largest medical cannabis programs in the world. The 2026 storyline is whether the country can convert that demand base into a domestic industry rather than an import market.

Key Takeaways

• Brazil now reports 873,000+ registered medical cannabis patients, putting it on par with Germany.
• Annual market revenue is approaching $200 million and growing rapidly.
• ANVISA has expanded rules in 2026 to allow selected patient associations to cultivate cannabis — a significant move toward a domestic supply chain.
• Most products are still imported, keeping prices elevated and creating headroom for major price drops as cultivation expands.
• The 5th Cannabis Fair at the Transamérica Expo Center, São Paulo (May 21–23, 2026) is the focal point for investors, operators and regulators across Latin America.

For U.S. consumers tracking the global cannabis-access story, the parallel reform here is access through licensed retail. Browse Budpedia's cannabis dispensary directory to find verified dispensaries in your state and city.

Explore cannabis news, find dispensaries, and join the community at Budpedia.